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Leprosy continues to be the belligerent public health hazard for the causation of high disability and 
eventual morbidity cases with stable prevalence rates, even with treatment by the on-going multidrug 
therapy (MDT). Today, dapsone (DDS) resistance has led to fear of leprosy in more unfortunate people 
of certain developing countries. Herein, DDS was chemically conjugated with five phytochemicals 
independently as dapsone-phytochemical conjugates (DPCs) based on azo-coupling reaction. Possible 
biological activities were verified with computational chemistry and quantum mechanics by molecular 
dynamics simulation program before chemical synthesis and spectral characterizations viz., proton-
HNMR, FTIR, UV and LC-MS. The in vivo antileprosy activity was monitored using the ‘mouse-foot-pad 
propagation method’, with WHO recommended concentration 0.01% mg/kg each DPC for 12 weeks, 
and the host-toxicity testing of the active DPC4 was seen in cultured-human-lymphocytes in vitro. 
One-log bacilli cells in DDS-resistant infected mice footpads decreased by the DPC4, and no bacilli were 
found in the DDS-sensitive mice hind pads. Additionally, the in vitro host toxicity study also confirmed 
that the DCP4 up to 5,000 mg/L level was safety for oral administration, since a minor number of dead 
cells were found in red color under a fluorescent microscope. Several advanced bioinformatics tools 
could help locate the potential chemical entity, thereby reducing the time and resources required for in 
vitro and in vitro tests. DPC4 could be used in place of DDS in MDT, evidenced from in vivo antileprosy 
activity and in vitro host toxicity study.
Multidrug therapy (MDT) with the sulphonamide drug, dapsone (4, 4′-diamino diphenyl sulfone or, DDS), along 
with antibiotics, rifampicin, clofazimine, and ofloxacin is the ongoing treatment option for leprosy, recommended 
by World Health Organization (WHO) today1–4. Its causative bacillus Mycobacterium leprae (Ml) had been under 
control by DDS in monotherapy since 1935. Today, DDS resistance has become one of the major obstacles for 
the control of leprosy with eventual treatment failure2,5,6. Consequently, the disease burden has reached to an 
alarming level of approximate 2,33,000 Ml cases globally; while, approximately 1,35,000 Ml cases with 5, 858 
(~63%) cases of disability were recorded from India in 20163. Nearly ~2,00,000 new cases are detected annually 
worldwide, with the highest prevalence in developing countries such as India, Nepal, Myanmar, Brazil, China, 
Madagascar, etc.1,3. DDS cannot be ordinarily replaced, despite its basic primary of morbidity from body intoler-
ance, since it is the first-line drug for leprosy7,8.
Dihydropteroate synthase (DHPS) is one of the nodal enzymes in the biosynthetic process of folic acid, which 
is essential for bacterial survival, while the human body derives folic acid from diets. DDS is an analog of the 
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bacterial precursor para-aminobenzoic acid (pABA), which competitively inhibits the biosynthesis of bacte-
rial folic acid, by targeting the putative DHPS enzyme9,10. Point mutations in the folP1 gene-encoded DHPS, at 
codons 53 and 55 positions for Thr53 and Pro55, respectively (Fig. 1), are characteristic molecular signatures of 
DDS-resistance2,11,12. Recently, rifampicin was reported to be ineffective against Ml13,14. Thus, there is a look for 
an additional alternative potent agent(s) against leprosy in a relatively short time, as DDS-resistant bacilli spread 
fast. Continuing with wild-type (Wt) and mutant-types (Mt) forms of MlDHPS as the identified targets15, the 
development of chemically altered DDS inhibiting bacterial folic acid synthesis had been organised1.
In the present study, based on structural suitability, DDS was chemically conjugated individually with five phy-
tochemicals namely, 4-hydroxy coumarin, eugenol, salicylic acid, thymol and vanillin for aiming at the enhance-
ment of its potency. The antileprosy efficacy and drug-likeness characteristics of proposed DDS-phytochemical 
conjugates (DPCs) were screened through chemoinformatics- and structural bioinformatics-tools viz., prediction 
of activity spectra for substances (PASS), molecular docking and molecular dynamic (MD) simulations with pos-
sible toxicity profile prediction in an ideal drug development approach, before the direct synthesis of conjugates. 
MlDHPS enzyme represents the most suitable target for the possible development of the potential antileprosy 
drug. However, due to the lack of atomic resolution structure of MlDHPS, the homology model of the protein was 
developed and validated by stereo-chemical quality tools before the molecular docking-simulation study with 
the conjugates. To cross-check the computational results and to get antileprosy physical activity, five proposed 
conjugates were synthesized and characterized by several spectral techniques, Fourier-transform infrared spec-
troscopy (FTIR), UV-spectroscopy, proton nuclear magnetic resonance (1HNMR), liquid chromatography-mass 
spectrometry (LCMS). Antileprosy activities of synthesized conjugates were tested in ‘mouse-foot-pad propaga-
tion’ (MFP) method using both DDS sensitive and resistant strains after inducing the disease by infecting mice; 
and the active most conjugate was selected for toxicity study using cultured human lymphocytes in vitro, isolated 
from umbilical cord blood (UCB).
Materials and methods
MlDHPSs and DPCs 3D-structures modelling and validation. Proposed five DPCs were designed 
based on azo-coupling reaction (Fig. 2) using ChemDraw Ultra 10.0 software similar to one reported earlier1,9. 
The retrieved DSS from the PubChem database (CID: 2955) and designed DPC structures were used in PDB 
file format, for molecular docking against the target MlDHPS. The target protein sequence i.e., DHPS of Ml 
was obtained from the public domain UniProtKB (ID: P0C0X1). BLASTp (http://blast.ncbi.nlm.nih.gov/) and 
HHpred (http://toolkit.tuebingen.mpg.de/hhpred), suggested a consensus template. Later the target-template 
alignment generated using MultAlin (http://www.sacs.ucsf.edu/cgi-bin/multalin.py) (as shown in Fig. S1) was 
used for theoretical modelling of MlDHPS with comparative modelling protocol of MODELLER9v18 tool2. The 
structural geometry of the generated MlDHPS model was validated using the ‘Structure analysis and verification 
server (SAVE)’ and ProSA-web (https://prosa.services.came.sbg.ac.at/). After generation of this model, five muta-
tions were introduced into the certified Wt structure at positions two positions Thr53 (T53I, T53A, and T53V) 
and Pro55 (P55R and P55L) generate five mutants as Mt targets, using BIOVIA Discovery Studio (BIOVIA DSV 
v4.5).
possible biological activity and toxicity prediction of the proposed Dcps. The predicted bio-
logical activities of the desired compounds were assessed on probable activity (Pa) and probable inactivity (Pi) 
values. Herein, antimycobacterium, antileprosy, antituberculosis, and antiinfective and activates of DPCs and 
DDS, through the PASS program (http://www.pharmaexpert.ru/passonline/). Based on the highest Pa value as 
suggested by PASS analysis, a compound can be selected and considered as the possible active drugable agent9. 
Additionally, ProTox (http://tox.charite.de/tox/) tool was employed to calculate the likely toxicity profiles, toxicity 
class and LD50 values of DPCs and DDS.
Figure 1. Diagrammatic presentation of the mutation event of MlDHPS enzyme at folP1 site confirming 
DDS resistance. At codons 53 and 55, the enzyme mutates sequences coding Ala or Ile or Val and Arg or Leu, 
respectively.
3Scientific RepoRtS |         (2020) 10:6839  | https://doi.org/10.1038/s41598-020-63913-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Molecular docking of DPCs against wild and mutant MlDHpSs. Molecular docking study was con-
ducted using AutoDock 4.2, where both the Wt and Mt type model of MlDHPS served as candidate target and 
DDS/DPCs treated as ligands. Kollman charges for target protein structures, whereas Geister partial charges were 
used for ligands through AutoDock Toolsv1.5. Binding site information based on the structural superposition 
with the close structural homolog co-crystallized with the drug was obtained from the published literature16. The 
grid was spaced around the binding site residues with a grid spacing 0.375 Å, with the threshold population size 
of 300 and the maximum number of energy calculations to 2.5 × 107. The docked conformations from AutoDock 
were scored and clustered based on an RMSD cut-off of 2 Å. The top-ranked poses with higher biding free energy 
and ligand efficiency were subjected to all-atom molecular dynamics simulations in GROMACS to assess the 
structural integrity of the docked complexes.
All-atom molecular dynamics simulation study. The dynamic behaviours of each MlDHPS DDS/ 
DPCs complex was investigated using all-atom molecular dynamics simulations using Amber-99sb ILDN force 
field in TIP3 water models employed in GROMACSv5.11,17–19. A three-step approach was employed for simu-
lation studies, which include heating the system followed by equilibration and at the last the production run at 
300 K for 40 ns for each system. The Linear Constraint Solver (LINCS) algorithm and the Particle Mesh Ewald 
(PME) method were employed to compute the electrostatic, hydrogen and covalent bond interactions for each 
protein-ligand complexes. The resultant trajectory was harvested at intervals of 20 ps for the analysis of pot 
dynamics.
trajectory analysis. Gromacs utility tools were employed for trajectory analysis. The quality assurance 
parameters like backbone RMSD, C-alpha root mean square fluctuations, a radius of gyration and intermolec-
ular hydrogen bonds were computed using gmx rms, gmx rmsf, gmx gyrate, and gmx hbond utility toolkits of 
GROMACS17,18. Two-dimensional graphs depicting the dynamic stability were plotted using the Xmgrace tool. 
BIOVIA DSV was used to compute the inter-molecular interaction. In order to observe the highest amplitude 
records and correlated motions in complex systems, the most potent statistical technique, principal component 
analysis (PCA) was employed1,17–19. In this study, the covariance matrix of Cα-atoms of the complex systems was 
built using gmx covar tool. To comprehend the global motion of complexes (in phase space), the eigenvectors and 
eigenvalues were calculated, later projected into the phase space along the first two principal components (i.e., 
PC1 and PC2) using gmx anaieg tool.
MM/PBSA binding free energy analysis. The calculations of binding free energy play a decisive role in 
understanding the dynamic interaction between ligands and the target protein. The molecular mechanics based 
MM/PBSA method used in g_mmpbsav5.12, compatible with GROMACS, was used to compute the binding free 
energy (ΔGbind) of each system, using the snapshots from the MD trajectories. The binding free energy (ΔGbind) 
was calculated using the following equations:
Δ = − − = Δ + Δ −G G G G E G T S (1)bind complex protein ligand MM sol
Δ = Δ + Δ = Δ + Δ + ΔE E E E ( E E ) (2)MM bonded nonbonded bonded vdw ele
Figure 2. Stepwise synthesis process of DDS-phytochemical conjugates (DPCs).
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Δ = Δ + ΔG G G (3)sol polar nonpolar
From the resultant 40 ns trajectories, 400 snapshots were extracted at equal intervals for binding energy esti-
mations. The procedure for calculation of binding free energy was adopted from previous studies1,17–19.
Synthesis and structural interpretation of Dpcs. An ice-cool sodium nitrite solution of molarity equal 
to DDS was added dropwise with an 8 mL volume of concentrated HCl, and 8 mL water serially on an ice bath; 
after completion of the diazotization, the reaction was followed by pouring of ice-cool solution of 0.03 mol of 
individual phytochemicals in volumes of 20 mL 10% sodium hydroxide solution, as described earlier1,9,17. The 
resultant mixture was maintained at pH 5 to 6, and the obtained products were filtered and recrystallized with 
ethanol. Structures of the desired phytochemical conjugates were interpreted by several spectral techniques1,9. 
The open capillary method was used for the determination of melting points of the synthesized conjugates. The 
solvent-behaviour pattern of conjugates was studied by an UV-visible spectrophotometer. LCMS was performed 
for mass fingerprinting with pure conjugates analyzed through a Waters UPLC 1200 SQD-Mass Detector.
Dapsone resistance Ml and DHPS mutation confirmation. DDS-sensitive and -resistant Ml strains 
were obtained from the Animal House Facility of Leprosy Centre, Karigiri, and all experiments with live animals 
were performed after approval of Institutional ethical committee, ‘Karigiri Research Committee of The Schieffelin 
Institute of Health Research & Leprosy Centre’, with relevant guidelines and regulations for use of mice (sub-
mission ID: 2014–2674, dated 18th Dec. 2014). These strains were passaged routinely in the hind foot pads of 
cross-bred (CBA) albino mice. Briefly, the sensitive strains of Ml were obtained from skin biopsies of leprosy 
cases, which were collected at diagnosis in the hospital and whose bacteriological index is >3+ at sites of skin 
lesions. These cases were later known to respond to MDT and were confirmed to have no mutations in folP1 gene, 
corresponding to dihydropteroate synthase in Ml as the determinant of DDS resistance20. After grinding of biopsy 
samples in ‘mortar and pestle’ with the normal saline and a part of the suspension of bacilli, DNA extraction 
had been pursued using DNeasy Kits (Cat No: 69504, Qiagen Inc.). Extracted DNA samples were stored in 1X 
Tris EDTA buffer at −20 °C until further use. PCR was performed using folP detection primer with appropriate 
reactions and conditions for the confirmation of DDS resistance, as published20. DNA sequencing was carried 
out using the commercial facility (Scigenome Pvt. Ltd. Cochin, India) that confirmed the presence of mutations 
within the respective amplicons. The sequence reads were analyzed for quality and available mutations, using 
Molecular Evolutionary Genetics Analysis version 7.0 (MEGA).
Assessment of antileprosy activity. Immuno-compromised (thymectomized irradiated, TR) CBA 
mice were used to multiply the identified strains of Ml to prepare sufficient inoculum for the experiments, as 
described20,21. The mice were maintained on a normal diet for 8–10 months for the infection to be established, 
and the counts were raised to a minimum of 1 × 106 cells per hind foot pad, as per WHO guidelines. These mice 
were then inducted into the experimental groups for testing of the synthesized conjugates. For the current study, 
previously infection-established mice in the hind foot pads were chosen as detailed: five normal mice and five TR 
mice having DDS resistant strains, and five TR mice containing DDS sensitive strains. Those were divided into 
five groups for the to-be-tested drugs administered in the diet at the concentration of 0.01%, which was similar to 
the normal DDS concentrations used in screening for drug-resistant strains. The treatment duration lasted for 12 
weeks, which was fixed based on the proportional bactericidal technique equating the WHO standard regimen of 
MB MDT in humans. After the treatment for graded durations, mice were euthanized and Ml cells were extracted 
from the hind footpads and enumerated subsequently. Enumerations were performed adopting methods that 
were employed for estimating the bacteriological index in human tissue samples20,21.
Host-toxicity study of DPC4. The host toxicity of the effective most conjugate, DPC4 was carried out with 
cultured human lymphocytes purified from UCB22. DDS and DPC4 treated culture plates with different dosages 
(mg/L) against lymphocytes and incubated. The cytotoxicity was assessed using the acridine orange/ ethidium 
bromide (AO/EB) staining and the 3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide (MTT) assay 
and cells were checked by a fluorescent microscope (Magnus). Cell toxicity was assessed basing transformed pro-
bit values (Finney’s method) and those converted from percent lethality (PL) values, which were potted against 
corresponding log10 values of DDS and DPC422.
Results
three-dimensional architecture of MlDHpS. The template i.e., the crystal structure DHPS of M. tuber-
culosis (PDB ID: 1EYE) had a sequence identity of 77% and query coverage of 100% was considered as the most 
appropriate template (Table S1), for comparative modelling of the target enzyme structure MlDHPS (Figs. S1 and 
S2). Based on the Modeller scoring function and least Cα-root mean square deviation (RMSD) with the template, 
the best model was selected and optimized. The Ramachandran plot for the proposed model portrayed the Phi/
Psi distribution of amino acids within the acceptable range, indicating its accuracy. A total of 94.4% residues fell 
in the most favored region, and the rest 5.6% residues were in the additional allowed area, while none of the resi-
dues fell in the disallowed region signifies the good quality of the constructed model (as shown in Fig. S3A). From 
ProSA-web, the Z-score energy profile of the generated model was −8.95, which matched with the Z-score range 
of experimentally derived template structures (as displayed in Fig. S3B; Table S2). The quality and consistency 
of the MlDHPS model were validated using ProQ and METAMQAPII; the generated model was accepted for 
further studies based on the overall structural analyses (Table S2). Finally, the generated five mutants were used as 
targets against five newly designed DPCs as ligands in molecular docking investigation, to evaluate the strength 
of binding affinity using the software Auto Dock 4.2.
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possible biological activity and toxicity prediction of the proposed Dcps. Concomitantly, anti-
mycobacterial, antiinfective, antileprosy, antituberculosis activities of the proposed DPCs were recorded using 
the PASS program (as summarized in Table 1). From PASS prediction values, it was confirmed that the DPC4 
had the most effective antileprosy ‘Pa’ values or Possible active values, 0.755 > 0.001, while the individual DDS 
‘Pa’ values were 0.663 > 0.002. Similarly, all proposed DPCs had significantly effective ‘Pa’ values for antimyco-
bacterial agents from which, DCP4 had the highest antimycobacterial ‘Pa’ value, 0.754 > 0.004; whereas, the DDS 
had ‘Pa value’ 0.647 > 0.007. Thus, PASS prediction indicated that all conjugates were active as antimycobacterial 
agents, and only the DPC4 was the most suitable conjugate against leprosy in the drug development endeavor. 
Furthermore, predicted toxicity, as toxicity class and lethal dose 50 (LD50) value too were assessed using the tool 
ProTox (Table 1). It was ascertained that DPC4 had LD50 values, 5000 mg/kg with toxicity class V (five); whereas 
the DDS had the LD50 value, 250 mg/kg with toxicity class III (three) (Table 1). Based on the determination of 
toxicity classes and computed LD50 values, it could be concluded that the described DPCs are comparatively less 
toxic and safe molecules; particularly, DPC4 could be a regarded as the active most antileprosy agent, with a low 
level of host toxicity and reasonably safe enough than the DDS.
Analysis of docking-simulations. The resultant docked poses were screened to get the best conforma-
tion based on the highest docking score, ligand effectiveness and intermolecular hydrogen-bonds (as displayed 
in Table 2). Molecular docking analysis presented (represented in negative energy) that most of the DPCs had 
higher binding energy values than that of the DDS. From docking results, it was evident that the DPC4 (DDS 
with thymol) had a comparatively higher negative binding energy, −11.78, −10.84, −11.33, −11.38, −11.15 and 
−10.87 kcal/mol. In contrast, the individual DDS had −4.91, −4.91, −4.95, −5.01, −4.84, and −4.89 kcal/mol 
against the Wt and five Mt MlDHPSs, respectively. Intermolecular analysis of DPCs with Wt and Mt MlDHPSs 
displayed that the DPC4 complexes were stabilized through comparatively the highest numbers of intermolecular 
Hydrogen-bonds and electrostatic interactions. Therefore, DPC4 with Wt and Mt MlDHPSs was considered to 
monitor the protein-ligand interaction and optimization, through molecular dynamics simulation in aqueous 
solutions.
Analysis of MD trajectories and intermolecular H-bond analysis. MD simulations offer to probe 
the behavioral dynamics of bio-macromolecules including proteins and systems at length scales ranging from 
nanometres to close to a micrometer and concomitantly on microsecond timescales. In this study, the employed 
all-atom MD simulations of protein-ligand complexes were considered to explore in detail of interactions of 
DPCs/ DDS with both Wt and Mt MlDHPS enzyme individually at a molecular scale. To measure the dynamic 
stabilities of each complex, the backbone RMSD, Rg, Cα-RMSF and inter-molecular H-bonds from the resultant 
trajectories were computed. The trend in RMSD of all systems rapidly increased up to 5 Å during the initial ten 
nanoseconds (ns) and after that, a relatively constant value ~2.47–3.37 Å was maintained with little exceptions 
for the Wt MlDHPS with DPC4 and DDS bound T53I (Fig. 3A). During the first 1–35 ns MlDHPS with DPC4 
DCs/DPCs
Prediction of activity spectra for substances (PASS) Toxicity profile
Antimycobacterial Antileprosy Antituberculosic Antiinfective TC LD50
DPC1 0.695 > 0.005 0.321 > 0.008 0.691 > 0.004 0.443 > 0.033 V 2100
DPC2 0.648 > 0.022 0.298 > 0.010 0.423 > 0.025 0.285 > 0.115 V 5000
DPC3 0.739 > 0.005 0.544 > 0.002 0.748 > 0.004 0.818 > 0.005 IV 2000
DPC4 0.754 > 0.004 0.755 > 0.001 0.728 > 0.004 0.740 > 0.005 V 5000
DPC5 0.693 > 0.005 0.371 > 0.005 0.690 > 0.004 0.292 > 0.109 V 5000
DDS* 0.647 > 0.007 0.663 > 0.002 0.610 > 0.005 0.751 > 0.005 III 250
Table 1. Predicted antimycobacterial, antileprosy, antituberculosic and antiinfective activities (Pa > Pi) and 
toxicity profiles of DPCs using prediction of activity spectra for substances (PASS) programme and ProTox 
tool. DDS*, standard dapsone; DPC, dapsone-phytochemical conjugate; LD50, lethal dose value (mg/kg); TC, 
toxicity class.
DCs/DPCs













DPC1 −10.816 −10.614 −10.630 −10.676 −10.512 −10.305
DPC2 −10.762 −10.480 −10.497 −10.547 −10.793 −10.403
DPC3 −10.754 −10.249 −10.047 −10.523 −10.438 −10.249
DPC4 −11.785 −10.844 −11.339 −11.381 −11.155 −10.875
DPC5 −10.531 −9.797 −10.164 −9.525 −9.552 −10.055
DDS* −4.910 −4.910 −4.950 −5.010 −4.840 −4.890
Table 2. Docking scores and predicted toxicity class with LD50 values of DPCs along with dapsone against 
target enzyme MlDHPS.
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and the T53I with DDS systems displayed slightly higher RMSD as compared to the other systems; however, 
both systems attained stable RMSD after 30 ns. Unlike the RMSD, the other stability parameter Rg followed 
slightly a different trend, where all complexes had decreased the radius of gyration (Rg of ~18.57 Å), indicating 
the compactness of the systems till 40 ns (Fig. 3B). The flexibility among the residues upon ligand binding can be 
inferred from the trend in average root mean square fluctuation (RMSF) of Cα-atom with respect to time. It can 
be witnessed that all the protein-ligand complexes followed a more or less similar trend in RMSF with minute 
exceptions in a few cases (Fig. 3C). The 310 helix, loops adjoining helix and strand along with variable loops, with 
some higher peak values displayed a comparatively high degree of fluctuations in the respective Cα atoms in all 
systems signifies the flexibility of these residues. A reason behind the recorded higher RMSF values with certain 
residues and Cα-RMSF of binding site residues were the higher fluctuations; those indicated corresponding close 
participation in ligand/ drug binding events.
For scrutinization of intermolecular H-bonding patterns in MlDHPS-DDS/DPC4 complexes, an intermolec-
ular H-bond analysis was performed for six complex systems. It was evident that six systems displayed differential 
patterns of H-bonding (Fig. 4A). H-bond analysis between the DPC4 with Mt (P55R) DHPSs yielded discern-
ibly higher numbers of H-bonds (~4.12), followed by those of T53I with DPC4. Despite there was a significant 
deviation in H-bonds during the initial 20 ns, stability was maintained untill 40 ns (Fig. 4A). In some cases, for 
example, DPC4 with Wt and DDS with Mt, a few H-bonds were seen to be broken during MD, which was com-
pensated through newer electrostatic and hydrophobic contacts. Adaptations in intermolecular H-bonds and 
other non-bonded interactions were witnessed before and after MD simulations in all protein-ligand systems 
impeccably, which corroborated the similar analysis of RMSF values; the existence of differences in residue flexi-
bility of complexes was demonstrated.
principal component analysis. The snapshots extracted from complex trajectories were projected onto 
the phase space to obtain a range of eigenvectors (EVs) or principal components (PCs), which represent the vec-
torial illustration of each single element of the motion indicating the direction of individual movement. Several 
studies have shown that the top of the first few eigenvectors (EVs) capture bulks of the internal motions; however, 
the first two eigenvectors were considered (EV1 and EV2), which accounted for values more than 80% of overall 
recorded motions projected into the phase space. As it is, eigenvalues obtained from each EV describe the active 
movement of each component to the motion. The obtained steep curves of eigenvalues in ‘plots of eigenvalues 
against the respective eigenvectors’ (Fig. 4B), covering around 92.1, 89.3, 87.5, 82.0, 94.8 and 84.2%, progressively, 
the backbone motions were recorded increasing initially by 30 eigenvectors. Movements of both states of Wt and 
Mt MlDHPS complex systems in phase space were obtained by projecting the trajectories that were acquired onto 
the first two EVs (Fig. 4C). Least differential scattering images of atoms were observed in all cases, which specify 
the occurrence of least conformational changes in the complex structures, in agreement with MD analysis. The 
overall flexibility of DPCs/ DDS bound structures was inferred by the trace of the diagonalized covariance matrix 
of central chain atoms. The T53I with DDS (trace value, 28.47 nm2) and Wt with DPC4 (trace value, 28.37 nm2) 
complex systems displayed a little higher scattering of atoms with high trace values in each, with eventual con-
firmation of the overall increased flexibility in case of Wt-complex than Mt form having been well supported by 
RMSF analysis. Furthermore, to explore the conformation heterogeneity in the ensemble of complex structures 
obtained from each trajectory, the GROMOS clustering algorithm was employed with an RMSD cut-off at a value 
of 0.2 nm. Indeed, the RMSD of clusters were within the range of ~0.123 to 0.178 nm, and the clusters with the 
maximum numbers of representatives were visually inspected for protein-ligand interactions using BIOVIA DSV 
(Fig. 5). It was concluded as the DPC4 strongly interacted with the Mt MlDHPS as compared to DDS.
Figure 3. Conformational stability of MlDHPS‐DDS/DPC4 complexes during 40‐ns time period indicated 
in different color graph. (A) RMSD of MlDHPS‐DDS/DPC4 complexes; (B) Rg of MlDHPS‐DDS/DPC4 
complexes; (C) Cα‐RMSF profile of the target, MlDHPS‐DDS/DPC4 complexes during 40 nano second 
molecular dynamic simulation.
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Pre- and Post-MD docking simulation and MM/ PBSA binding free energy analysis. Obtained 
from the clustering approach, the representative structures were used for the interactive analysis of DPC4 with Wt 
and Mt MlDHPSs, individually (Table S3). Before MD, a total of two H-bonds were found between Wt MlDHPS 
with DPC4 at the amino acid position, Asp21 with 3.15 Å and Gly50 with 2.0 Å distance, respectively. On another 
hand after MD, three H-bonds were formed with Arg139, Tyr141, and Arg139 having atomic distances, 2.34, 
1.67 and 3.17 Å, respectively (Table S3B). Furthermore, pi-pi stacking, pi-sulfur, and pi-alkyl interactions were 
also noticed with Arg214, Glu51, Asp21, Phe182 and Pro230, before MD in the Wt MlDHPS-DPC4 complex. 
Furthermore in the Wt complex, more pi-cation interactions with Phe19, Tyr141, Phe19 and Tyr141, pi-anion 
with Glu51, more pi-alkyl interactions with Phe19, Trp132, Tyr141, Pro140, and Ala112 were observed. In the 
Mt MlDHPS (P55R)-DPC4 complex, a total of two H-bonds were observed in Asp21 with the interaction dis-
tance, 2.90 Å and Gly50 with the distance 2.13 Å. Along with pi-cation in Arg214, pi-anion in Asp21 and Glu51, 
pi-sulfur in Phe182, pi-pi stacked in Phe182, pi-alkyl in Pro230 and Lys213 positions were observed before MD 
(Table S3F). While Gly181 formed H-bond interactions with DCP4, Arg24 had interaction as pi-cation, and 
Trp132 as pi-pi stacked, Phe182 as pi-pi along with Phe19, Trp132, Trp132, Tyr141, Phe182, Arg214, and Met135 
having been contributed as pi-alkyl interactions with an average of ~3 to 4 Å distances, seen after MD simulations. 
Thus, Phe19, Val107, Tr132 and Tyr141 could be stated as important amino acids towards the strong molecular 
inhibition of DPC4 with the modelled MlDHPSs pterin binding pocket. The cross verification with the selected 
templates, the pterin binding pocket with amino acids had the significant role of interaction with drugs, corrobo-
rating the earlier report16. Additionally, it can be summarized that apart from intermolecular H-bonds, the other 
non-bonded contacts involving hydrophobic and electrostatic contacts play active roles in the MlDHPS-DPC4 
mediated interaction (Fig. 5).
To understand the driving force behind molecular recognition of DPCs/DDS against MlDPHSs, the binding 
free energies were estimated using snapshots from MD trajectories using the MM/PBSA method. The discrete 
energy components, EMM, Gpolar, and Gnonpolar of each complex contributing towards binding free energy were 
summarized (Table S3). Computed binding free energy values of DDS to Wt and Mt MlDHPS complexes were 
within the range of −26.92 ± 0.46 to −50.10 ± 0.85 kJmol−1; while for the designed DPCs had energy values 
Figure 4. (A) Stability of MlDHPS‐DDS/DPC4 complexes inferred through intermolecular Hydrogen‐bonds; 
(B) Principal component analysis of the DCP4/DDS interacted with the target enzyme, MlDHPS of both wild‐
type and mutant‐type structures. Eigenvalues for the MlDHPS‐DCP4/DDS bound models as a function of 
eigenvector and the plot displays the eigenvalues of only the first 20 eigenvectors; and (C) The cloud represents 
the 40‐ns trajectories projected onto the first two eigenvectors, EV1 and EV2. The X‐axis and Y‐axis show the 
projection of the structures of the backbone atoms in the molecular dynamics trajectories of complexes onto the 
phase space defined.
Figure 5. Molecular interactions of DPC4 with mutant MlDHPS (P55R) during docking. The interactions 
image was generated using BIOVIA DSV and interacted amino acids are highlighted.
8Scientific RepoRtS |         (2020) 10:6839  | https://doi.org/10.1038/s41598-020-63913-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
in the range of −112.30 ± 1.02 to −166.29 ± 1.93 kJmol−1, respectively. The predictable negative electrostatic 
interactions were for Wt/Mt MlDHPSs-DDS/DPCs interaction symbolizing the electrostatic attractions between 
receptors and corresponding ligands (Fig. S4). The polar contributions for solvation were allocated positive values 
ranges within 84.76–299.53 kJ mol−1. DPCs possess comparatively higher negative free energy values for the Wt as 
well as, Mt MlDHPSs, as compared to DDS, concluded from the binding free energy analyses.
Synthesis and characterization of Dpcs. After the detailed computational analyses and good responses 
from there, all five proposed DPCs were synthesized by the azo-dye coupling method, and structural confor-
mations of individual conjugates were further ascertained. From the FTIR spectra of conjugates, DPC4 was 
seen with sharp absorption bands at 3366, 1355, 1145 and 1499 cm−1, due to the presence of phenolic hydroxyl 
-OH(str.) of thymol, asymmetrical and symmetrical stretching of the sulfone radical SO2(str.) and the newly 
inserted –N = N-(str.) entity, respectively; consequently confirming the described structural modifications of 
DDS (Fig. S5). Furthermore, solvatochromic effects of DPC4 in ethanol had been recorded having a strong 
bathochromic shift (λmax384), due to extensive chromophoric conjugation of thymol as compared with the pre-
cursor DDS. From the proton NMR of the synthesized DPC4 on DMSO-d6, it could be inferred that 8 aromatic 
double doublets protons are present at δ 8.17–8.39 ppm with respect to the DDS nucleus, and five singlet protons 
including two aromatics, two methyl and one board singlet OH proton of thymol were present that appeared at δ 
7.09, 7.64, 2.34, 1.25 and 9.69 ppm, respectively (Fig. S6). From LCMS study, the single quadrupole mass detector 
analysis confirmed predicted molecular formulae of conjugates; notably, the molecular fingerprint of DPC4 at 
m/z 566.13 in 1.20 min (retention factor) with a percent of area 95.81%, actively assigned the predicted chemical 
formula, C32H34N4O4S (Fig. S7). Similarly, the rest four DPCs were characterized (Supporting Information).
Dapsone resistance Ml and DHPS mutation confirmation. With preliminary demographic and clin-
ical characteristics of the leprosy cases, DNA was extracted from skin samples, using the lysis protocol for verifi-
cation of the DDS resistant strain of Ml. The ‘WHO Guidelines for Sentinel Surveillance Study of Drug Resistance 
in Leprosy’ was followed for detecting mutations using the mouse-foot-pad experiment with ancillary PCR tech-
nique, using the specific primer of folP gene for Ml. After confirmation of the DDS resistance band through PCR 
(Fig. S8), the presence of mutations in 53 and 55 coding positions within the amplified product was confirmed 
after DNA sequencing (Fig. S9). Sequence data were analyzed using MEGA Version-7 (Molecular Evolutionary 
Genetics Analysis) and Sequencer V. 5.4.6.
Antileprosy activity evaluation of Dpcs. DDS -sensitive and -resistant infected mice were administered 
with DPCs in the diet at the concentration 0.01%, which is similar to the average DDS concentrations used in 
screening for drug-resistant strains. The treatment duration was fixed for 12 weeks, based on the proportional 
bactericidal technique equating the WHO standard regimen of MB-MDT for humans. After the treatment dura-
tion, mice were euthanized and Ml bacilli cells were extracted from the hind footpads and enumerated. From in 
vivo evaluation, the DPC4 was found as the effective-most conjugate with a one-log reduction in resistant infected 
mice foot pads, and no bacilli were found in the sensitive hind pad of infected mice within 12 weeks of treatment. 
Blithely, the rest four conjugates reduced one-log in bacilli counts only in the 12 weeks of treatment similar to that 
of the DPC4 (Table 3). However, further pharmacological validation is required for the replacement of DPC4 in 
place of DDS in the presently used MDT regimen.
Host toxicity of the most active Dpc. Indeed, toxicity study is one of the critical parameters for authen-
ticating a newly synthesized chemical entity as a prospective drug candidate. The host toxicity of the active con-
jugated agent, DPC4 was studied using human lymphocytes from UCB, as it is a waste of blood from the hospital 
after infant birth. In the in vitro toxicity study with the concentration up to 5000 mg/L of DCP4, a minor number 
of dead cells were found in a fluorescent microscope. Cell toxicity was analyzed basing on transformed probit 
values (Finney’s method), and those converted from percent lethality (PL) values (Table S4), potted against corre-
sponding log10 values of DDS and DPC4 for a probit plot (Fig. 6). Indeed, the computational toxicity assessment 
was corroborated by the toxicity study in cultured human lymphocytes22. Thus, this systematic novel finding 
could be taken as an ideal approach towards the newer development of a conjugated against drug-resistant Ml.
Discussion
DDS resistance in leprosy was known during its implementation in the monotherapy treatment in 1966. This 
problem was addressed to a certain extent after the introduction of MDT by WHO in the year 1983, when the 
combinatorial regimens were used against paucibacillary and MB leprosy1,2. Nevertheless, with the emergence 
of resistance of DDS and rifampicin in recent years, the rates of relapsed leprosy cases with resistance to MDT 
gradually increased, posing a threat to public health. In this context, the introduction of a new drug or modifi-
cation of existing drugs in MDT is only a possible option to control drug-resistant leprosy, since no new drug 
candidate against leprosy is available, approved by WHO and FDA in the last two decades. Due to the associated 
complications and time killing studies of drug development against leprosy, failures are plenty for revising the 
current MDT in replacing DDS23–25. Thus the same three drugs, DDS, rifampicin and clofazimine were continued 
in use with an altered dose schedule since 1992. However, only the treatment interval for MB leprosy was reduced 
from 24 to 12 months through repurposing drug combination attempts with the new additions of ofloxacin and 
minocycline in rifampicin resistance case in between 1982–199824,25. However, the revised MDT too has been 
a persisting failure for DDS and rifampicin-resistant cases1,2; nevertheless, the time-consuming MFP method 
has been the conventional gold-standard method in detection of drug resistance pattern and antileprosy activity 
of a new drug, since the bacilli cannot be grown in vitro. When viewed from trenches of the management of 
this deadly disease, locating some clinically active DPC before synthesis, the use of a bandwagon of advanced 
bioinformatics tools is a dire necessity to save time and resources. In the present study, DPCs were developed 
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as probable effective antileprosy agents with the help of the azo-coupling reaction method. The recorded com-
putational results of PASS and toxicity profile predictions, RMSD, Rg and inter-molecular H-bonds analyses, 
MM/PBSA binding free energy values, along with van der Waals force accounts, electrostatic and SASA energy 
estimations approaches herein helped to get a decisive role in promoting the DPC4 as the suitable for synthesis 
as future agent in MDT. Indeed, the possible biological active values as an effective antileprosy agent from PASS 
prediction and the binding free energy score against the Mt MlDHPSs proclaimed that the DPC4 was significantly 
higher than those of DDS.
However, the generated simple scoring functions or docking scores obtained through docking program often 
disregards the noteworthy energetic contributions as solvation free energy, which is not ideal for the calculation 
of the binding affinity and correct binding pose of any small molecule or ligands. Hence, the exact ligand-binding 
pose was considered by integrating the docking program, all-atoms MD simulations and the binding free energy 
MM/PBSA method, since the latter approach had been seen as a practical and trustworthy approach to model 
molecular recognition mechanisms involving receptor-ligand binding interactions17–19. Amongst the popular clas-
sical simulation methods, the MM/PBSA method had been considered a valid and reliable way to model molecu-
lar recognition, including receptor-ligand binding interactions1,20,21. Structural characteristics of MlDHPS-DPC4 
and MlDHPS-DDS complexes, obtained from attempts with AutoDock, performed explicit solvent MD simula-
tions using the GROMACS package as illuminated. To quantify the structural dynamics and intrinsic stability of 







Bacilli cell counts 
before treatment
Bacilli cell counts 
after treatment
DPC1
Tr R 2.3*106 1.7* 106
N R 8.2*105 5.7* 105
Tr S 4*106 4.7* 105
DPC2
Tr R 1.3*106 5.6* 107
N R 1.6*106 5.6* 105
Tr S 6.7*106 1.4* 105
DPC3
Tr R 1.3*106 2.3* 106
N R 1.6*106 2.6* 106
Tr S 6.7*106 2.2* 105
DPC4
Tr R 5.8*105 2.6* 104
N R 6.1*105 4.8* 105
Tr S 5*105 no growth
DPC5
Tr R 5.8*105 2.5* 106
N R 6.1*105 6* 105
Tr S 5*105 6.4* 106
DDS
Tr R 1*105 1.3* 105
N R 7.4*105 1.4* 106
Tr S 4*106 1.3* 106
Table 3. Antileprosy activity of 5 DPCs along with individual dapsone (in concentration 0.01% mg/kg) in 
mouse foot-pad propagation method. The recorded bacilli cell counts after 3 months of treatment. N, normal; R, 
resistance; S: sensitive; Tr: immunocompromised (thymectomized irradiated).
Figure 6. The log10 concentration values were determined taking probit points of cytotoxicity ascertained by 
AO/EB staining and MTT assay; and probits were plotted for DPC4 during toxicity study with lymphocytes, for 
establishing toxicity.
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The dynamics analysis of these complexes suggested the complexes generated through docking retain the most of 
properties during MD. From free energy decompositions analysis it could be ascertained that the predominant 
force of the binding process for the DDS/ DPCs with Wt/ Mt MlDHPSs correlated van der Waals energy. Because 
the negative van der Waals energy occurs in all simulation systems, it can be considered that van der Waals plays 
a substantial role in forming stable complexes. In addition, the electrostatic energy and SASA energy accounts 
for binding free energy. This signifies the designed DPCs might be more superior to that of DDS, and the stated 
conclusion needs further in vivo investigation for its validity. However, the computed binding free energies cannot 
be taken absolute due to lack of in vivo experiments; nonetheless, the binding free energy study (without entropic 
contribution) has provided evidence on the molecular recognition of receptor MlDHPSs with DDS and DPCs. 
Now a day, MD simulation methods have become a monotonous tool in modern drug discovery processes. These 
techniques, for explicit structural flexibility and entropic effects, help to estimate thermodynamic features and 
associated underlying kinetics with receptor-drug recognition and binding precisely with novel computational 
algorithms. Hence more future studies, including novel MD methods may help in the discovery of novel drug 
candidate(s) for the protocol of multidrug therapy against leprosy in the future26–28.
In mainstream drug development, the conjugation of a secondary plant metabolite having suitability for chem-
ical compatibility with an inactive drug was considered as an ideal approach9. A similar type of work had been 
examined against cancer treatment as ‘antibody-drug’ or ‘antibody-cyanobacterial chemical’ pairs have gained 
importance as antimalarial and antibacterial drug development earlier29–33. Thus, this chemical conjugation is a 
new trend in antimicrobial drug development to enhance the activity and pharmacokinetic properties34–38.
conclusion
The obtained MFP results should be a milestone for the DPC4 in reducing one-log DDS resistant 
bacilli-population in vivo in three months of treatment only, and no bacilli were found in treating DDS sensitive 
Ml, simultaneously. The cytotoxicity study also helped to state that, after the conjugation of a phytochemical to 
DDS, the DDS-conjugate enhanced antileprosy activity in vivo with reduced host toxicity pattern in vitro. Overall, 
the systematic computational analysis, coupled with medicinal chemistry, the conjugation of a phytochemical 
with a clinically inactive mainstream drug, could be a new trend in the current drug discovery, as here.
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